Self-Assembly Dual-Responsive NO Donor Nanoparticles for Effective Cancer Therapy

Guolong Gu1,2, Chen Chen1, Shichao Zhang2

  • 1Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, People's Republic of China.

Insights

Novel nanoparticles deliver nitric oxide (NO) for targeted cancer chemotherapy. This strategy overcomes limitations of traditional drugs and enhances NO

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cancer Research

Background:

  • Classical chemotherapy faces drug resistance and severe side effects.
  • Nitric oxide (NO) exhibits potent antitumor activity but has poor in vivo delivery due to lipophilicity and short half-life.

Purpose of the Study:

  • To develop a novel targeted drug delivery system for nitric oxide (NO) in cancer chemotherapy.
  • To overcome the limitations of existing NO donors and delivery vehicles.

Main Methods:

  • Synthesized a prodrug dimer precursor (FZ-SS-FZ) from a nitric oxide donor (phenylsulfonylfuroxan, FZ) using disulfide and ester bonds.
  • Fabricated dual-responsive, tumor-targeting nanoparticles (FZ-SS-FZ@FA NPs) via self-assembly and folic acid functionalization.
  • Investigated self-assembly, NO release, and in vitro efficacy.

Main Results:

  • FZ-SS-FZ self-assembled into uniform nanoparticles in aqueous solution.
  • The nanoparticles effectively delivered NO to tumor cells, inducing specific NO release and apoptosis.
  • FZ-SS-FZ@FA NPs demonstrated significantly improved NO drug loading, delivery efficiency, and enhanced therapeutic efficacy.

Conclusions:

  • Developed a novel prodrug dimer self-assembly nanoparticle strategy for targeted NO delivery in cancer chemotherapy.
  • This approach provides a promising theoretical basis for the clinical translation of NO-based gas chemotherapy.
  • Offers a new avenue for enhancing cancer treatment efficacy through targeted NO delivery.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...